SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon informs about press release

28 Jan 2026 Evaluate
Biocon has informed that it enclosed the press release titled ‘S&P Global Upgrades Biocon Biologics Credit Rating To ‘BB+’ Revises Outlook to ‘Stable’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

425.15 2.15 (0.51%)
04-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1960.00
Dr. Reddys Labs. 1160.65
Cipla 1450.00
Lupin 2376.00
Zydus Lifesciences 1118.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: